Sarepta Duchenne Gene Therapy Wins Broader Use From FDA
Despite mixed results in testing, agency officials determined Elevidys showed enough to warrant a label that includes all patients at least 4 years of…
Carbon
Sequoia and IOA Re Announce Expansion Into Personal Accident Reinsurance
Conshohocken, PA, October 24, 2023 – Sequoia Reinsurance Services and IOA Re are pleased to announce a collaboration with Everest Reinsurance Company (“Everest”) and/or its affiliates to expand their…
Stop Loss Companies and Reinsurers Help Employers Tackle Key Challenges
The high cost of healthcare claims is just one of several market challenges facing self-insured employers today. The cost of preventable hospital-acquired conditions adds…
The Dangers, Cost of Weight Loss Drugs — How to Avoid a Life Sentence
Beyond being a major public health challenge, obesity carries extreme implications for employers and their teams. In fact, a recent report estimates obesity cost…
U.S. Allows Use of Gamida’s Therapy in Blood Cancer Treatment
The U.S. Food and Drug Administration said on Monday it had approved the use of Gamida Cell Ltd's (GMDA.O), opens new tab cell therapy for…
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic…
U.S. FDA Grants Accelerated Approval For Iovance’s Skin Cancer Therapy
Feb 16 (Reuters) - Iovance Biotherapeutics (IOVA.O), opens new tab said on Friday the U.S. health regulator has granted an accelerated approval for its cell therapy…
Vertex, CRISPR’s Gene-Editing Therapy Casgevy Wins Early FDA Nod
he FDA has approved Vertex and CRISPR's gene-editing therapy Casgevy to treat beta thalassemia. Casgevy becomes the first therapy for the rare blood disorder…
Wellness Program RESET: What Employers Should Expect From Vendors
A recent report published by McKinsey estimates that poor health costs the U.S. economy about $3.2 trillion annually from premature deaths and the lost…
Yescarta Receives U.S. FDA Approval
Landmark ZUMA-7 Study Demonstrated Patients on Yescarta Were 2.5 Times More Likely to Be Alive at Two Years Without Cancer Progression or Need for…
